Kornimate/medical-research-clean huggingface dataset:
combined endoscopic-laparoscopic sentinel lymph node navigation surgery in early gastric cancer

Conditions: Early Gastric Cancer

Summary: the main treatment for early gastric cancer (egc) include endoscopic submucosal dissection (esd) and radical gastrectomy. however, appropriate treatment for patients who exceed the absolute indications and noncurative resection of esd remains unestablished. combined endoscopic-laparoscopic sentinel node navigation surgery seems to be the promising solution according to previous study, however evidence-based medicine in china was lacking. it is imperative to establish its safety and efficacy in chinese patients with egc.


Eligibility criteria:
inclusion criteria: * 1) patients aged 18-80 years, regardless of gender. 2) patients with eastern cooperative oncology group (ecog) score ≤ 2 and american society of anesthesiologists (asa) score ≤ 2 who are candidates for a curative d2 gastrectomy. 3) patients without prior gastrointestinal surgery, chemotherapy, or radiotherapy. 4) patients with normal liver, kidney, heart, lung, and bone marrow function (gpt × 109 /l, plt\>109 /l). 5) patients capable of understanding and adhering to the research protocol. 6) patients who can provide written informed consent, either personally or through legal representative. 7) patients with ct1nxm0 gastric cancer or after non-curative esd resection, according to the uicc tnm staging system, 8th edition. exclusion criteria: * 1) patients with a contraindication for gastroscopy. 2) patients with uncontrollable diseases, such as coagulation disorders, epilepsy, central nervous system diseases or mental disorders, cardiopulmonary insufficiency, unstable angina, myocardial infarction, a cerebrovascular accident that occurred within 6 months, and other surgical contraindications. 3) patients unable to undergo general anesthesia or surgical treatment due to conditions related to other organs, or unwilling to undergo surgery. 4) patients with gastric stump cancer, recurrent gastric cancer, multiple primary malignant tumors in the abdominopelvic cavity, or a history of other malignant tumors within the previous 5 years. 5) pregnant or lactating women. 6) participants enrolled in other clinical trials. 7) patients with undeterminable tracer staining range or contraindications to tracer use. 8) patients who fail to receive or fail esd therapy. 9) patients who meet the absolute indication of esd.

Keywords: early gastric cancer sentinel lymph node basin dissection laparoscopic surgery safety and efficacy
gait recovery after stroke

Conditions: Stroke

Summary: the purpose of this observational study is to track the recovery of stance duration symmetry during the first 6 months after stroke using wearable sensors and explore the influence of stroke specific factors (time since stroke, stroke type, location and paretic side).

gait impairments can limit the ability to perform daily activities and increase the risk of falls in stroke survivors. although rehabilitation improves walking in people with stroke, it is unclear whether the improvement relies on compensatory strategies or can be further improved to achieve normal or closer to normal performance. stance duration symmetry is an ideal measure of gait recovery in stroke survivors as it indicates the paretic sides capacity to control body weight and maintain balance during walking. measuring stance duration symmetry may, therefore, be useful for monitoring gait recovery and could be considered as one of key goals in stroke rehabilitation. understanding the mechanisms of gait recovery in people with stroke is, therefore, essential for designing treatment program, setting realistic goals and appropriate timing for promoted intervention according to their stroke characteristics. our plan is to track changes in the symmetry of stance duration of hemiplegic patients during the first 6 months after stroke attached at the following time points: 1) at recruitment (within 2 weeks after of stroke), 2) 4th weeks (1 month) after stroke, 3) 12th weeks (3 months) after stroke, and 4) 26th weeks (6 months) after stroke. two wearable accelerometers (the activpal4+, pal technology, glasgow, uk) directly to the skin of both anterior thighs using sticky pads for 4 days (24 hours) period. demographic (age and gender) and relevant clinical data (10-meter walk test, modified rivermead mobility index (rmi), stroke type, paretic side) will also be recorded as factors to explain gait symmetry.

Eligibility criteria:
inclusion criteria: * aged 18 or older * diagnosis of a first occurrence of stroke by consultant stroke physician * medically stable * referred for rehabilitation * functional ambulatory category of 1 and over exclusion criteria: * acute skin condition * transient ischemic stroke * comorbidities that may interfere with walking function, such as parkinson's disease or lower limb amputation * severe communication impairments or delirium

Keywords: observational, gait, symmetry
a diagnostic study on patients with drug-induced liver injury

Conditions: Acute Drug-induced Liver Injury; Chronic Liver Disease

Summary: this study is a multi-center, prospective, non-interventional cohort study with an estimated enrollment of 600 patients with acute dili. according to the inclusion and exclusion criteria, the rucam scale and/or expert evaluation, patients with a clinical diagnosis of acute dili will be included in the study to establish a multi-center, prospective dili cohort. depending on the presence or absence of associated chronic liver disease, the patients will be divided into the basic dili group with chronic liver disease and basic dili group without chronic liver disease. all enrolled patients should complete at least six months of follow-up.

this study is a multi-center, prospective, non-interventional cohort study with an estimated enrollment of 600 patients with acute dili. according to the inclusion and exclusion criteria, the rucam scale and/or expert evaluation, patients with a clinical diagnosis of acute dili will be included in the study to establish a multi-center, prospective dili cohort. depending on the presence or absence of associated chronic liver disease, the patients will be divided into the basic dili group with chronic liver disease and basic dili group without chronic liver disease. all enrolled patients should complete at least six months of follow-up. this research will propose a new or optimized dili diagnostic scheme based on the analysis of the problems existing in the practice of rucam scale, the clinical characteristics and prognosis of dili, the exploration of biomarkers, and all the comprehensive information of big data from hepatox platform, and establish a big data-based diagnosis model or auxiliary diagnosis decision system.

Eligibility criteria:
inclusion criteria: * no restriction on age and gender. * patients need to meet one of the following biochemical thresholds for acute liver injury recommended by the international consensus: 1. alt \< 5 x uln 2. alp \< 2 x uln 3. alt 3 uln and tbil 2 uln * the duration of liver biochemical abnormalities does not exceed 90 days. * for the clinical diagnosis of acute drug-induced liver injury, the rucam scale ≥ 6 points is required. however, if the rucam scale score is 3-5 points, the opinions of 3 experts are needed to confirm the diagnosis of dili, and the patients can only be enrolled after the experts agree to it. * the patient signs the informed consent form after fully understanding the nature of the study, the nature of his/her disease, related treatment methods, and the potential risks associated with participating in the trial. exclusion criteria: * non-drug induced liver injury * an inability to complete the visits prescribed by the study
the effect of inhalation agent on the qtc interval during liver transplantation: sub study (nct01886664)

Conditions: Anesthesia, General

Summary: the purpose of this study is to assess the effects of inhalation agent on corrected qt interval duration during liver transplantation.


Eligibility criteria:
inclusion criteria: * elective liver transplantation exclusion criteria: * age \ 65 * patient refusal * re-transplantation
rapid development and implementation of a remote ecg-monitored prospective randomized clinical trial during a pandemic: hydroxychloroquine prophylaxis in covid-19 household contacts

Conditions: Covid19; Hydroxychloroquine; Coronavirus Infection; Transmission; Prophylaxis

Summary: * organizing an entirely no in-person contact clinical trial is feasible during a 22 covid-19 pandemic 23 * remote smartphone 6-lead ecg monitoring is possible even in a group unfamiliar 24 with the technology 25 * hydroxychloroquine used prophylactically at 200 mg bid had no observable 26 cardiotoxicity 27 * additional study using this technique is warranted to look at reliability and cost-28 effectiveness

household members were contacted by telephone and provided consent forms via e-mail electronic signatures. randomization was 2:1 to hcq 200 mg bid or observation for 10 days with total follow-up of 14 days. covid status was determined by home saliva pcr assay on days 1 and 14. study drug was shipped to participants. data of daily symptoms and 6-lead ecgs using a smartphone kardiamobile® 6l application were collected.

Eligibility criteria:
inclusion criteria: * exposure to a covid-19-infected individual in the same household within five days of diagnosis; * age \>18 years; * ability to give informed consent to participate in a clinical study; * ability to swallow oral medications; * access to a smartphone exclusion criteria: * allergy or intolerance to hydroxychloroquine (plaquenilr); * weight less than 85 pounds; * eye disease affecting the retina; * severe kidney or liver disease; * g6pd-deficiency; * porphyria; * long qtc ekg abnormality or family history of this; * other major ekg abnormalities; * taking medications that can affect the qt interval including flecainide, amiodarone, digoxin, procainamide, propafenone, sotalol, quinidine, dofetilide, levofloxacin, ciprofloxacin, azithromycin, erythromycin, amitriptyline, doxepin, desipramine, imipramine, fluoxetine, sertraline, venlafaxine, quetiapine, haloperidol, droperidol, thioridazine, ziprasidone, furosemide, sumatriptan or zolmitriptan, cisapride, arsenic, dolasetron, or methadone; * current pregnancy; * current hospitalization; * symptomatic with fever or cough; * lack of access to a smartphone
respiratory syncytial virus (rsv) follow-up study (mk-0476-374)

Conditions: Respiratory Syncytial Virus Bronchiolitis

Summary: this is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled mk-0476 protocol 272 (nct00076973) study of montelukast in the treatment of respiratory symptoms subsequent to rsv-induced bronchiolitis. the purpose of this study is to better understand the clinical and demographic correlates of asthma and atopic disorders in children (through the age of 6 years) with a history of severe rsv-induced bronchiolitis.


Eligibility criteria:
inclusion criteria: * successfully completed mk-0476 protocol 272 * had rsv-induced bronchiolitis at entry into protocol 272 exclusion criteria: * had developed or had been diagnosed with any illness or congenital disorder that could be immediately life threatening

Keywords: asthma
management of prostate cancer in central china

Conditions: Prostate Cancer

Summary: some recent reports indicate that incidence of prostate cancer is increasing rapidly in china. however, no large-scale survey of prostate cancer has been done in central china, few data are available regarding its management. the investigators aimed to analyze the management of prostate cancer and compare the outcome of patients with such a survey. the investigators collected data of patients diagnosed with prostate cancer from the 2003 and 2008 in central china. data were disaggregated by rural and urban hukou. the survival rate of patients was analyzed using kaplan-meier method. prognostic factors were analyzed using the log-rank test and cox proportional hazards model.


Eligibility criteria:
inclusion criteria: * patients with newly diagnosed prostate cancer were included in the study. exclusion criteria: * those with a history of prostate cancer who were treated for another disease were excluded from study.

Keywords: prostatic neoplasms prostate cancer disease management rural urban
intermittent antimalaria treatment with sp in african children

Conditions: Malaria; Anemia

Summary: - intermittent preventive treatment with sp in children to evaluate efficacy and safety of this drug combination in children in northern ghana

* sulfadoxine and pyrimethamine have long been used for malaria prevention and treatment. in this study, following suggestions of who, these drugs are used for intermittent treatment. * it will be tested if this approach reduces the number of malaria attacks and ameliorates the severity of the disease * it will also be determined if anemia due to malaria, which is prevalent in northern ghana, may be reduced * moreover, the interaction between red cell polymorphisms such as hbs, hbc, alpha-thalassemia and glucose-6-phosphate dehydrogenase deficiency and sp will be examined

Eligibility criteria:
inclusion criteria: * informed consent by parents or guardian * no concomitant serious disease * age \>2 months exclusion criteria: * serious allergy or hypersensitivity to sulfonamides or pyrimethamine * no severe hepatic or renal dysfunction * serious breach of study protocol

Keywords: intermittent preventive treatment ipti malaria control ghana
effects of inspiratory muscles strengthening among coronary patients on the sleep apnea obstructive syndrome

Conditions: Sleep Apnea, Obstructive; Acute Coronary Syndrome

Summary: obstructive sleep apnea (osa) syndrome affects up to 5% of the general population. the prevalence is multiplied by 13 in coronary artery disease (cad) patients. many studies have shown that osa syndrome was the main risk factor for cardiovascular morbidity and mortality (rr = 9.1 \[95%, 2.6 to 31.2\]). if the value of treatment with continuous positive airway pressure (cpap) in symptomatic cad patients (daytime sleepiness and/or 2 clinical symptoms with apnea hypopnea index (ahi) ≥ 20) appears to be established, treatment with cpap in asymptomatic cad patients (with ahi\> 30) may be too demanding. alternative treatments are rare and results are highly variable. therefore, it would be interesting to suggest other treatment modalities with moderate coronary and/or minimally symptomatic osa syndrome.

this study aims to assess the relevance of inspiratory muscles strengthening on reducing ahi in cad patients with moderate osa (ahi between 15 and 30).

Eligibility criteria:
inclusion criteria: * patients with moderate osa (15 \<ahi \<30) * period between acute coronary syndrome and inclusion \<60 days * patients included in cardiac rehabilitation exclusion criteria: * obstructive lung disease with tiffeneau index less than 70%. * restrictive lung disease with a reduction of total lung capacity (tlc) * treatment for osa or clinical context (comorbidity) justifying cpap * congestive heart failure, thoracic surgery by sternotomy * spontaneous pneumothorax * severe asthma * ruptured eardrum, or another disease of the middle ear, or acute sinusitis

Keywords: obstructive sleep apnea resistive inspiratory muscle training coronary artery disease cardiac rehabilitation
clinical decision support algorithm to predict diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: diabetic retinopathy (dr), a complication of diabetes, is a leading cause of blindness among working-aged adults globally. in its early stages, dr is symptomless, and can only be detected by an annual eye exam. once the disease has progressed to the point where vision loss has occurred, the damage is irreversible. consequently, early detection is quintessential in treating dr. two barriers to early detection are poor patient compliance with the annual exam and lack of access to specialists in rural areas. this research is focused on developing and validating new, cost-effective predictive technologies that can improve early screening of dr. our overall objective is to develop and implement an entire suite of tools to detect diabetes complications in order to augment care for underserved rural populations in the us and internationally.


Eligibility criteria:
inclusion criteria: for diabetic patients with dr: * with 250.xx diabetes and 362.0x dr icd-9 codes * all variables are complete within the observation window for diabetic patients without dr: * with 250.xx diabetes icd-9 codes * without 362.0x dr icd-9 codes * all variables are complete within the observation window
effects of giving interleukin-2 (il-2) plus anti-hiv therapy to hiv-positive patients with cd4 cell counts of at least 350 cells/mm3

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate the safety and tolerability of giving il-2 plus anti-hiv (antiretroviral) therapy to hiv-positive patients with cd4 cell counts (cells of the immune system that fight infection) of at least 350 cells/mm3. this study will also examine the ability of antiretroviral therapy combined with il-2 to boost the immune system. il-2, given through injection under the skin, in combination with anti-hiv therapy can increase cd4 cell counts. this study examines 3 doses of il-2 in order to determine the safest and most effective dose to use.

interleukin-2 administered subcutaneously, in combination with antiretrovirals, results in an increased cd4+ cell count that might impact upon hiv disease progression. a phase iii trial involving large numbers of hiv-positive patients is the next step in the development process. to develop appropriate clinical experience with this combination, this phase ii trial will allow administration of il-2 plus antiretroviral therapy to a small number of patients in sites being considered for the phase iii trial. patients receive antiretrovirals alone or antiretrovirals plus il-2 given subcutaneously. three doses of il-2 are studied, with 12 patients evaluated at each dose. when at least 9 of the first 12 patients complete the 5-day dosing period without dose-limiting toxicity, the next 12 patients are treated at the next highest dose every 12 hours for 5 days every 8 weeks; when this dose is tolerated, the last 12 patients randomized receive the highest study dose every 12 hours for 5 days every 8 weeks. patients enrolled at the first two doses of il-2 who complete three courses of treatment have their dose escalated to a maximum of the highest study dose.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * have a cd4 cell count greater than or equal to 300 cells/mm3. * have no aids-defining illnesses. * are at least 18 years old. * have been on antiretroviral therapy for at least 7 days prior to study entry. exclusion criteria patients will not be eligible for this study if they: * abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that would affect their safety or ability to complete the study. * have a history of cancer (other than kaposi's sarcoma), an aids-defining illness, a central nervous system abnormality, or an autoimmune/inflammatory disease. * are pregnant or breast-feeding. * have ever received il-2.

Keywords: injections, subcutaneous interleukin-2 dose-response relationship, drug drug therapy, combination cd4 lymphocyte count anti-hiv agents
predicting outcome of total knee replacement surgery in patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee; Arthroplasty, Replacement, Knee

Summary: osteoarthritis (oa) is the main cause of pain and disability in elderly. for knee oa, a total knee replacement (tkr) is an effective surgical treatment, and the majority of patients report substantial pain relief and functional improvement following surgery. however, 20-40% of patients undergoing tkr are dissatisfied with postsurgical outcome. even after revision, some patients keep complaining of persisting pain. in this study, the investigators will examine putative prognostic factors on the basis of the biopsychosocial model. besides several psychological factors (measured with questionnaires), the investigators will assess structural impairments (such as radiographic severity of oa), functional impairments (muscle weakness and proprioceptive deficits), anesthetic procedures, immediate postoperative pain management, metabolic factors (body composition and hemoglobin a1c), inflammatory factors (c-reactive protein) and the investigators also will examine the role of altered central pain processing (cpp) (primary and secondary mechanical hyperalgesia, mechanical temporal summation, thermal primary and secondary hyperalgesia, endogenous pain modulation). with a longitudinal study design, this study will explore which factors are predictive of poor outcome in knee oa patients after tkr. moreover, the interrelationship between cpp, structural, functional, metabolic, inflammatory and psychological factors, and the clinical expression of knee oa (pain, symptoms, physical performance and quality of life) will be investigated. further research on the role of the aforementioned putative prognostic factors on postsurgical outcome could contribute to better management of these patients, since these factors may be particularly important for patient-tailored treatment.


Eligibility criteria:
inclusion criteria: * knee oa patients \>40 years awaiting tkr surgery. both men and women of all ethnical backgrounds are included. exclusion criteria: * patients with diagnosis of neurological/ systemic diseases, possibly impacting pain * patients who are not capable of understanding and speaking dutch * revision surgery
personality traits and its impact on quality of life and clinical outcome evaluation in crohn's patients

Conditions: Crohn's Disease

Summary: quality of life is recommended as one of essential parameters to evaluate treatment effect and clinical outcome in patients with crohn's disease (cd). recent studies reported that several disease-unrelated variables may affect quality of life in cd patients. this study is dedicated to investigate the influence of various personality traits on quality of life, and whether or not they should be taken into account when evaluating clinical outcomes in patients with cd.

this is a prospective, single-center study. all enrolled patients are divided into 2 groups: * group 1: quiescent cd group (cdai≤150 points) * group 2: active cd group (cdai\>150 points) all enrolled patients are required to accomplish the following questionnaires at visit: * inflammatory bowel disease questionnaire (ibdq) * neuroticism (n) and lie (l) subscale of the eysenck personality inventory (epi) * hospital anxiety and depression scale (hads) * buss-perry aggression (bpa) questionnaire all questionnaires are translated and validated in chinese population.

Eligibility criteria:
inclusion criteria: * 18-65 years old * a definite diagnosis of cd exclusion criteria: * current or previous mental disorders * receiving or once received psychotherapy * presence of major medical conditions (such as necessity of an operation) * chronic disease history other than inflammatory bowel disease * unwilling to participate in or cannot accomplish current study

Keywords: crohn's disease inflammatory bowel disease quality of life personality neuroticism